A recent study in bladder cancer showed that SMARCB1-deficient tumours displayed increased IL6–janus kinase–signal transducer and activator of transcription 3 (IL6-JAK-STAT3) signalling in in vivo models and patient tumours, believed to be associated with metastasis. This evidence concerns the gene IL6 and urinary bladder cancer.